000162010 001__ 162010 000162010 005__ 20251017144618.0 000162010 0247_ $$2doi$$a10.1016/j.eimce.2022.06.014 000162010 0248_ $$2sideral$$a144589 000162010 037__ $$aART-2023-144589 000162010 041__ $$aeng 000162010 100__ $$aPintado, V. 000162010 245__ $$aExecutive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant Gram-negative bacteria 000162010 260__ $$c2023 000162010 5203_ $$aInfections caused by multidrug resistant Gram-negative bacteria are becoming a worldwide problem due to their increasing incidence and associated high mortality. Carbapenem-resistant bacteria such as Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii are the most important in clinical practice. The objective of these guidelines is to update the recommendations for the diagnosis and treatment of infections caused by these multidrug resistant bacteria. Although ‘old’ antibiotics such as aminoglycosides, colistin, or tigecycline are frequently used for therapy of these bacteria, the ‘new’ beta-lactams such as ceftazidime–avibactam, ceftolozane–tazobactam, meropenem–vaborbactam, imipenem–cilastatin–relebactam or cefiderocol are progressively becoming the first-line therapy for most of these microorganisms. The Spanish Society of Infectious Diseases and Clinical Microbiology (Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica) designated a panel of experts in the field to provide evidence-based recommendations in response to common clinical questions. This document is primarily focused on microbiological diagnosis, clinical management, and targeted antimicrobial therapy of these infections, with special attention to defining the role of the new antimicrobials in the treatment of these bacteria. 000162010 540__ $$9info:eu-repo/semantics/closedAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/ 000162010 590__ $$a2.6$$b2023 000162010 591__ $$aMICROBIOLOGY$$b92 / 161 = 0.571$$c2023$$dQ3$$eT2 000162010 591__ $$aINFECTIOUS DISEASES$$b69 / 132 = 0.523$$c2023$$dQ3$$eT2 000162010 592__ $$a0.288$$b2023 000162010 593__ $$aInfectious Diseases$$c2023$$dQ3 000162010 593__ $$aMicrobiology (medical)$$c2023$$dQ4 000162010 593__ $$aMicrobiology$$c2023$$dQ4 000162010 594__ $$a2.1$$b2023 000162010 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000162010 700__ $$aRuiz Garbajosa, P. 000162010 700__ $$aAguilera, D. 000162010 700__ $$aBaquero Artigao, F. 000162010 700__ $$aBou, G. 000162010 700__ $$aCantón, R. 000162010 700__ $$aGrau, S. 000162010 700__ $$aGutiérrez Gutiérrez, B. 000162010 700__ $$aMachuca, I. 000162010 700__ $$aMartínez Martínez, L. 000162010 700__ $$aMilagro Montero, M. 000162010 700__ $$0(orcid)0000-0001-9262-2461$$aMorte Romea, E.$$uUniversidad de Zaragoza 000162010 700__ $$aOliver, A. 000162010 700__ $$0(orcid)0000-0002-9600-8116$$aPaño Pardo, J.R.$$uUniversidad de Zaragoza 000162010 700__ $$aSorlí, L. 000162010 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000162010 773__ $$g41, 6 (2023), 360-370$$pEnferm. infecc. microbiol. clín.$$tEnfermedades Infecciosas y Microbiologia Clinica$$x0213-005X 000162010 8564_ $$s441258$$uhttps://zaguan.unizar.es/record/162010/files/texto_completo.pdf$$yVersión publicada 000162010 8564_ $$s2738126$$uhttps://zaguan.unizar.es/record/162010/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000162010 909CO $$ooai:zaguan.unizar.es:162010$$particulos$$pdriver 000162010 951__ $$a2025-10-17-14:20:47 000162010 980__ $$aARTICLE